By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Drugs A-Z > General > Amikacin

Amikacin

GMJ
Last updated: 02/06/2026 14:30
By
Prof. Giorgi Pkhakadze
Share
5 Min Read
SHARE
3 min read|603 words

Amikacin: Antibiotic Drug Profile

What is Amikacin?

Amikacin is a powerful antibiotic that belongs to the aminoglycoside class of medications. It is primarily used to treat serious bacterial infections caused by gram-negative bacteria that are resistant to other antibiotics. This medication is typically reserved for severe infections when other treatment options have failed or are not suitable.

Uses

Amikacin is prescribed for several serious bacterial infections:

  • Severe urinary tract infections – Used when other antibiotics have failed or bacteria show resistance to first-line treatments
  • Respiratory tract infections – Including pneumonia and other lung infections caused by susceptible bacteria
  • Septicemia (blood poisoning) – Life-threatening infections where bacteria have entered the bloodstream
  • Skin and soft tissue infections – Serious wounds, burns, or surgical site infections
  • Intra-abdominal infections – Infections within the abdomen, often following surgery or trauma

How it works

Amikacin works by interfering with bacterial protein synthesis, which is essential for bacterial survival and reproduction. It binds to specific parts of bacterial ribosomes (the protein-making machinery), causing the bacteria to produce defective proteins that ultimately lead to bacterial cell death. This mechanism makes it particularly effective against rapidly dividing bacteria.

Side effects

Common side effects:

Submit Your Paper
GMJ_Submit_Banner
  • Nausea and vomiting
  • Diarrhea
  • Headache
  • Injection site reactions (pain, swelling, redness)
  • Dizziness
  • Skin rash
  • Loss of appetite
  • Fatigue

Serious side effects requiring immediate medical attention:

  • Hearing loss or ringing in ears (ototoxicity)
  • Kidney damage (signs include decreased urination, swelling)
  • Severe allergic reactions (difficulty breathing, facial swelling)
  • Muscle weakness or paralysis
  • Severe diarrhea that may indicate intestinal infection

Warnings and precautions

  • Kidney function monitoring: Regular blood tests are essential as amikacin can cause kidney damage, especially in patients with existing kidney problems or those taking other nephrotoxic medications
  • Hearing assessment: Periodic hearing tests may be necessary as the drug can cause permanent hearing loss, particularly with prolonged use or high doses
  • Pregnancy considerations: Amikacin crosses the placenta and may harm the developing fetus, potentially causing eighth cranial nerve damage and hearing loss in the baby
  • Elderly patients: Older adults are at higher risk for kidney and hearing problems and may require dose adjustments and closer monitoring
  • Muscle disorders: Patients with myasthenia gravis or other neuromuscular disorders should use this medication with extreme caution as it can worsen muscle weakness

Interactions

  • Other aminoglycosides: Increased risk of kidney and ear toxicity when used with similar antibiotics like gentamicin or tobramycin
  • Loop diuretics (furosemide): May increase the risk of hearing damage and kidney toxicity
  • Vancomycin: Combined use significantly increases the risk of kidney damage
  • Cisplatin: Cancer chemotherapy drug that can amplify kidney and hearing toxicity
  • Non-steroidal anti-inflammatory drugs (NSAIDs): May reduce kidney function and increase amikacin toxicity
  • Neuromuscular blocking agents: Amikacin can prolong muscle paralysis during surgery
  • Cyclosporine: Immunosuppressive drug that may increase kidney toxicity risk
  • Amphotericin B: Antifungal medication that can increase nephrotoxicity when combined with amikacin

Check interactions with the GMJ Interaction Checker

Dosage

Amikacin is typically administered intravenously or intramuscularly in hospital settings. Adult dosing is usually calculated based on body weight and kidney function, commonly ranging from 15-20 mg per kilogram of body weight per day, divided into one or two doses. Treatment duration typically ranges from 7-10 days, though this may vary depending on the infection type and patient response. Blood levels are frequently monitored to ensure effectiveness while minimizing toxicity. Dosage must always be individualized and determined by a healthcare provider based on the specific infection, patient factors, and laboratory results.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

Cite this page

GMJ News Desk. "Amikacin." GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/drug/amikacin/

CC BY 4.0This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).

Was this article helpful?

Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
FDA’s Pazdur Calls for Agency Restructuring Amid China Competition and Internal Upheaval

FDA's Rick Pazdur calls for fundamental agency restructuring following internal disruption, citing…

Revolution Medicines Ships Experimental Pancreatic Cancer Drug Under Early Access

Revolution Medicines begins expanded access program for daraxonrasib targeting KRAS G12C mutations.…

NHS Patient Watchdog Abolition Sparks Concerns Over Health Service Accountability

Local councils warn that government plans to abolish NHS patient watchdogs will…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Milk Thistle (Silymarin)

By
Prof. Giorgi Pkhakadze
02/06/2026

Ranolazine

By
Prof. Giorgi Pkhakadze
02/06/2026

Copper supplements

By
Prof. Giorgi Pkhakadze
02/06/2026

Azathioprine

By
Prof. Giorgi Pkhakadze
02/06/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up